News >

CAR-T Paving New Path in Relapsed/Refractory Myeloma

Kristi Rosa
Published: Friday, Feb 07, 2020

Peter M. Voorhees, MD, Levine Cancer Institute

Peter M. Voorhees, MD

Although novel immunotherapy approaches have not proven to be curative in heavily pretreated patients with relapsed/refractory multiple myeloma, the strategy is resulting in unprecedented responses and progression-free survival (PFS) benefits, according to Peter Voorhees, MD.

“You can look at [CAR T-cell therapy] from either a 'glass half full' or 'glass half empty' perspective,” said Voorhees. “Glass half empty [means]: It's not curative, patients are still progressing, and the median PFS with, say, idecabtagene vicleucel (ide-cel; bb2121), was 12 months. On the other hand, [if we look at it from a] glass half full [perspective], then: We've never seen anything like this before in this group of patients. A median PFS of 12 months in this patient population is unheard of.”

Topline results from the pivotal phase II KarMMA trial (NCT03361748) showed that treatment with ide-cel resulted in a 73.4% overall response rate (ORR) in patients with relapsed/refractory disease, meeting the trial’s primary endpoint.1 Furthermore, the complete response (CR) rate with the BCMA-targeted CAR T-cell product was 31.3% and the median duration of response was 10.6 months.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication